Half-year report · Q2
2934.TEDINET S100VCMY
Period2024-06-01 → 2024-11-30
Filed2025-03-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Amends S100V313. Amended by S100VCX6 (2025-03-06).
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.8bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥17.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.0bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Operating income | ¥131m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | −¥221m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥112m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | −¥643m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥232m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥118m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | −¥233m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥8m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.1bn | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥287m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥53m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | −¥284m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥9.1bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥7.4bn | at 2023-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.5bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥9.1bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.7bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥1.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2023-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥13m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥971m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥220m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥300m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥139m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥933m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥1.58 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-426.06 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-59.33 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥1.56 | 2024-06-01 → 2024-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 12.7% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 10.8% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥180m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.7bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.6bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥96m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥24m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥11m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥100m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥2m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥236m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥10.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥109m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥312m |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥290m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.4bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.3bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥114m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥19m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥958,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥44m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥8.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥8.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥115m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥69m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 533
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in financing activities | Prior1YTDDuration | 933186000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -139171000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -338151000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 67751000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1588360000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1752966000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 1250209000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 1820717000 | JPY |
| Ec advertising expenses sga | Prior1YTDDuration | 1894576000 | JPY |
| Ec advertising expenses sga | CurrentYTDDuration | 2093906000 | JPY |
| Depreciation sga | Prior1YTDDuration | 17605000 | JPY |
| Depreciation sga | CurrentYTDDuration | 11089000 | JPY |
| Amortization of goodwill sga | Prior1YTDDuration | 102156000 | JPY |
| Amortization of goodwill sga | CurrentYTDDuration | 146571000 | JPY |
| Amortization of customer related assets | Prior1YTDDuration | 51935000 | JPY |
| Amortization of customer related assets | CurrentYTDDuration | 39217000 | JPY |
| Provision for bonuses selling expenses | Prior1YTDDuration | 21753000 | JPY |
| Provision for bonuses selling expenses | CurrentYTDDuration | 21479000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 540000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 46098000 | JPY |
| Provision for point card certificates | Prior1YTDDuration | -11601000 | JPY |
| Provision for point card certificates | CurrentYTDDuration | -8594000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 3675578000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareSalesBusinessReportableSegmentMember | 2016127000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 2322277000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 8013983000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 8013983000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 958000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareSalesBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 114413000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 115372000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -115372000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 3676537000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareSalesBusinessReportableSegmentMember | 2016127000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 2436690000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 8129356000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -115372000 | JPY |
| Net sales | Prior1YTDDuration | 8013983000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 44362000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareSalesBusinessReportableSegmentMember | 5612000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 18827000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 68801000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -290128000 | JPY |
| Operating income | Prior1YTDDuration | -221327000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 3074821000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E33800-000HealthcareSalesBusinessReportableSegmentMember | 3182747000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 4586269000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 10843838000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |